Epix predictably happy

After an early disappointment out of the starting gate, Epix Pharmaceuticals Inc. now has put a second leg under its efforts to monetize its acquisition of neurology platform company Predix Pharmaceuticals Inc. earlier this year.

Last week, Epix (EPIX, Lexington, Mass.) said it would receive $35 million up front from GlaxoSmithKline plc in exchange for EPIX's PRX-03140 and three other programs for GPCR targets that the companies will pick jointly...